Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Laramée

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 22, 2023
Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021Jean-Baptiste Trouiller, Philippe Laramée
BMC Public Health|September 1, 2016
Economic burden associated with alcohol dependence in a German primary care sample: a bottom-up studyJakob Manthey, Philippe Laramée, Steve Parrott, et al.
Annals of Internal Medicine|August 17, 2011
Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guidelineJonathan Mant, Abdallah Al-Mohammad, Sharon Swain, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 31, 2016
The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol DependencePhilippe Laramée, Melissa Bell, Adam Irving, et al.
Annals of Internal Medicine|June 8, 2011
National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical ExcellenceDavid Wonderling, Laura Sawyer, Elisabetta Fenu, et al.
Journal of Psychopharmacology (Oxford, England)|September 10, 2015
Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality riskMichael Roerecke, Per Sørensen, Philippe Laramée, et al.
Pharmacoeconomics - Open|December 14, 2023
The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and SpainBérengère Macabeo, Théophile Rotrou, Aurélie Millier, et al.
CNS Drugs|February 17, 2016
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal PerspectiveThor-Henrik Brodtkorb, Melissa Bell, Adam H Irving, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 2, 2025
The Acceptance of Overall Survival Extrapolation Methods in Solid Tumor Treatments by Health Technology Assessment Agencies in England, France, and Australia between 2017 and 2022Jean-Baptiste Trouiller, Arthur Quenéchdu, Mondher Toumi, et al.
Heart (British Cardiac Society)|December 14, 2012
Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failurePhilippe Laramée, David Wonderling, Sharon Swain, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 22, 2023
Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021Jean-Baptiste Trouiller, Philippe Laramée
BMC Public Health|September 1, 2016
Economic burden associated with alcohol dependence in a German primary care sample: a bottom-up studyJakob Manthey, Philippe Laramée, Steve Parrott, et al.
Annals of Internal Medicine|August 17, 2011
Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guidelineJonathan Mant, Abdallah Al-Mohammad, Sharon Swain, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 31, 2016
The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol DependencePhilippe Laramée, Melissa Bell, Adam Irving, et al.
Annals of Internal Medicine|June 8, 2011
National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical ExcellenceDavid Wonderling, Laura Sawyer, Elisabetta Fenu, et al.
Journal of Psychopharmacology (Oxford, England)|September 10, 2015
Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality riskMichael Roerecke, Per Sørensen, Philippe Laramée, et al.
Pharmacoeconomics - Open|December 14, 2023
The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and SpainBérengère Macabeo, Théophile Rotrou, Aurélie Millier, et al.
CNS Drugs|February 17, 2016
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal PerspectiveThor-Henrik Brodtkorb, Melissa Bell, Adam H Irving, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 2, 2025
The Acceptance of Overall Survival Extrapolation Methods in Solid Tumor Treatments by Health Technology Assessment Agencies in England, France, and Australia between 2017 and 2022Jean-Baptiste Trouiller, Arthur Quenéchdu, Mondher Toumi, et al.
Heart (British Cardiac Society)|December 14, 2012
Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failurePhilippe Laramée, David Wonderling, Sharon Swain, et al.
Pageof 3